Reports Q4 revenue $64.5M vs. $68M a year ago. Given uncertainties surrounding the U.S. market for HETLIOZ for the treatment of Non-24 as a result of the ongoing HETLIOZ patent litigation, Vanda is unable to provide 2023 financial guidance at this time. Vanda will continue to evaluate its ability to provide financial guidance as the year progresses.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VNDA:
- Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
- Vanda Pharmaceuticals reports ‘positive’ results from Phase 3 study of Fanapt
- Vanda says court granted temporary injunction to prohibit generic Hetlioz entry
- Biotech Alert: Searches spiking for these stocks today
- Vanda Pharmaceuticals intends to appeal Hetlioz ANDA litigation decision